We were delighted to speak with Prof. Amy S. Paller (Northwestern University Feinberg School of Medicine, Chicago, IL, USA) about the results from the phase 3, LIBERTY AD PEDS trial (NCT03345914). This double-blind, 16-week study investigated duplimuab in children with atopic dermatitis.
Her abstract entitled ‘Dupilumab Provides Clinically Meaningful Improvement in Atopic Dermatitis (AD) Signs, Symptoms, and Quality of Life in Children With Severe AD: Results From the LIBERTY AD PEDS Phase 3 Clinical Trial’ was presented at the AAD VMX, 23-25 April 2021.
- What were the aims and design of the LIBERTY AD PEDS study? (0:24)
- What were the primary and key secondary endpoints of this study? (1:22)
- How well were these endpoints met? (2:10)
- Where do you see dupilumab sitting in the future treatment paradigm for atopic dermatitis in children? (4:12)
Disclosures: Prof. Amy Paller has acted as a consultant with honorarium for AbbVie, Abeona, Alcimed, Almirall, Amagma, Anaptysbio, Arena, Azitra, BiomX, Boehringer Ingelheim, Castle Biosciences, Catawba, Dermira, Eli Lilly, Exicure, Forte, Galderma, Kamari, Leo, Lifemax, NAOS, Novartis, Pfizer, Phoenix, Pierre Fabre, Sanofi/Genzyme, Seanergy, Trifecta and UCB; and an investigator (to institution) for AbbVie, Eli Lilly, Janssen, Regeneron, Incyte and UCB
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Gina Furnival.
Filmed in coverage of the AAD VMX 2021.
Share this Video
Related Videos In Atopic Dermatitis
Brian Kim, EADV 2021: Difelikefalin for Pruritus in Atopic Dermatitis
It was a pleasure to meet up with Dr Brian Kim (Washington University School of Medicine, St. Louis, MO, USA) to talk about the use of difelikefalin in treating pruritus associated with atopic dermatitis (AD). His presentation entitled ‘Oral Difelikefalin Reduces Pruritus in Atopic Dermatitis’ was given at the EADV 30th Congress, 29 Sep – […]
Andy Blauvelt, EADV 2021: Switching from Dupilumab to Upadacitinib in Atopic Dermatitis
It was a pleasure to speak with Dr Andy Blauvelt (Oregon Medical Research Center, Portland, OR, USA) about the results from the recent open-label study investigating the efficacy and safety of switching from dupilumab to upadacitinib in the treatment of atopic dermatitis. His presentation entitled ‘Efficacy and Safety of Switching from Dupilumab to Upadacitinib in […]
Kim Papp, AAD VMX 2021: Ruxolitinib Phase 3 Subgroup Analysis
It was a pleasure to speak with Dr Kim Papp (Probity Medical Research, Waterloo, ON, Canada) around the efficacy and tolerability of ruxolitinib cream in the treatment of atopic dermatitis (NCT03745638 & NCT03745651). The abstract ‘Efficacy of Ruxolitinib Cream for the Treatment of Atopic Dermatitis by Baseline Clinical Characteristics: Pooled Subgroup Analysis From Two Randomized […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!